Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?

Saved in:
Bibliographic Details
Published inGastroenterology (New York, N.Y. 1943) Vol. 165; no. 1; pp. 5 - 10
Main Authors Ratziu, Vlad, Friedman, Scott L.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.07.2023
Online AccessGet full text

Cover

Author Friedman, Scott L.
Ratziu, Vlad
Author_xml – sequence: 1
  givenname: Vlad
  surname: Ratziu
  fullname: Ratziu, Vlad
  organization: Sorbonne Université, Hôpital Pitié-Salpêtrière, Institute for Cardiometabolism and Nutrition, INSERM UMRS 1138 CRC, Paris, France
– sequence: 2
  givenname: Scott L.
  surname: Friedman
  fullname: Friedman, Scott L.
  organization: Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, New York
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32439497$$D View this record in MEDLINE/PubMed
BookMark eNp9kEtLw0AUhQepaH38A5Es3STeeeWxUaQ-oeqiisthMrmxU9JMnUmF_ntTUl26Olw45x7Od0RGrWuRkDMKCQXJLxfJpw6ddwkDBgnIBES6R8ZUsjwGoGxExr2ksYRcHpKjEBYAUPCcHpBDzgQvRJGNSf4x30S3Lpq56Fm3m-jFtboxbu4aa6JZh7pzc1zpznY2RG_e6iZE99o21ydkv-4PPN3pMXm_v3ubPMbT14enyc00NiITXZwJMDUzWV2yioqyEHWKeZrltMw4FpqzOuUZRaxKpsscOAiBUsq0xIqBTDk_JhfD35V3X2sMnVraYLBpdItuHRQTkHLoZ22tYrAa70LwWKuVt0vtN4qC2jJTCzUwU1tmCqTqmfWx813Dulxi9Rf6hdQbrgYD9ju_LXoVjMXWYGU9mk5Vzv7f8APQVX83
CitedBy_id crossref_primary_10_3390_jcm10010036
crossref_primary_10_1007_s11901_023_00629_0
crossref_primary_10_1038_s41591_023_02602_2
crossref_primary_10_1038_s44321_023_00011_z
crossref_primary_10_3350_cmh_2020_0136
crossref_primary_10_1038_s41401_022_00874_x
crossref_primary_10_1002_ctd2_9
crossref_primary_10_1016_j_jhep_2022_09_021
crossref_primary_10_3390_metabo12060528
crossref_primary_10_1038_s41598_021_85679_4
crossref_primary_10_1016_j_jhep_2022_04_002
crossref_primary_10_1053_j_gastro_2020_09_065
crossref_primary_10_1038_s41598_021_83974_8
crossref_primary_10_3389_fimmu_2021_749646
crossref_primary_10_1038_s41598_023_28647_4
crossref_primary_10_1136_flgastro_2023_102472
crossref_primary_10_1093_nutrit_nuad054
crossref_primary_10_1038_s41586_020_2938_9
crossref_primary_10_3390_metabo14010040
crossref_primary_10_1016_j_jhep_2023_10_015
crossref_primary_10_1038_s41598_021_99008_2
crossref_primary_10_3390_jcm10030492
crossref_primary_10_3390_livers4010010
crossref_primary_10_1016_j_ijbiomac_2021_06_093
crossref_primary_10_3390_cancers15225458
crossref_primary_10_3389_fendo_2022_1035159
crossref_primary_10_1016_j_jhep_2020_08_028
crossref_primary_10_1097_HEP_0000000000000780
crossref_primary_10_1111_liv_14799
crossref_primary_10_1111_liv_14675
crossref_primary_10_3390_ijms231911689
crossref_primary_10_1007_s12325_024_02885_y
crossref_primary_10_14218_JCTH_2020_00151
crossref_primary_10_1080_17512433_2023_2259306
crossref_primary_10_1016_j_jhepr_2021_100237
crossref_primary_10_1016_j_molmet_2024_101962
crossref_primary_10_1126_scitranslmed_adi0759
crossref_primary_10_1007_s40618_023_02216_y
crossref_primary_10_3389_fmed_2021_615978
crossref_primary_10_1016_j_metabol_2020_154342
crossref_primary_10_1016_j_jceh_2021_09_001
crossref_primary_10_1080_13543784_2021_1951701
crossref_primary_10_3350_cmh_2020_0181
crossref_primary_10_1007_s12325_021_01690_1
Cites_doi 10.1038/srep33453
10.1126/scitranslmed.add3949
10.1016/j.cmet.2019.11.006
10.1053/j.gastro.2019.11.296
10.1198/000313001300339950
10.1056/NEJMoa2036205
10.1016/j.jhep.2022.01.011
10.1053/j.gastro.2021.07.025
10.1016/j.jhep.2021.12.024
10.1136/jcp.2005.032391
10.1016/j.jhep.2019.11.008
10.1002/hep.30199
10.1016/j.jhep.2019.10.023
10.1053/j.gastro.2013.11.049
10.1371/journal.pone.0075361
10.1053/j.gastro.2018.07.027
10.1016/j.jhep.2021.02.037
10.1074/jbc.M209673200
10.1002/hep.25606
10.1038/s41591-022-02016-6
10.1073/pnas.0511167103
10.1002/hep.30590
10.1001/jamanetworkopen.2019.12565
10.1002/hep.28264
10.7326/M15-1774
10.1016/S0140-6736(12)61425-1
10.1053/j.gastro.2005.03.084
10.1038/nature10809
10.1016/j.jhep.2021.12.003
10.1016/j.cell.2017.09.016
10.1016/j.jhep.2020.02.027
10.1002/hep.31539
10.1053/j.gastro.2018.07.006
10.1016/j.jhep.2019.11.024
10.1016/S0016-5085(03)00907-7
10.1016/j.jhep.2020.06.025
10.1002/hep.29477
10.1002/hep.23478
10.1056/NEJMoa0907929
10.1038/s41591-021-01489-1
10.1016/j.jhep.2022.04.040
10.1111/j.1600-065X.2009.00794.x
10.1053/j.gastro.2014.06.043
10.1016/j.jhep.2010.09.020
10.1002/hep.20701
10.1126/science.aaw4361
10.1016/j.cgh.2014.07.037
10.1016/j.jhep.2021.10.013
10.1053/j.gastro.2004.07.015
10.1002/hep.22216
10.1016/j.jhep.2020.04.001
10.1016/j.jhep.2020.03.006
10.1038/s41591-021-01495-3
10.1016/j.jhep.2016.12.005
10.1002/hep.31687
10.1016/S0140-6736(19)33041-7
ContentType Journal Article
Copyright 2023
Copyright_xml – notice: 2023
DBID NPM
AAYXX
CITATION
7X8
DOI 10.1053/j.gastro.2020.05.046
DatabaseName PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1528-0012
EndPage 10
ExternalDocumentID 10_1053_j_gastro_2020_05_046
32439497
S0016508520306806
Genre Journal Article
GrantInformation_xml – fundername: Gilead Sciences
  funderid: https://doi.org/10.13039/100005564
GroupedDBID ---
--K
.1-
.55
.FO
.GJ
0R~
1B1
1CY
1P~
1~5
3O-
4.4
457
4G.
53G
5GY
5RE
5VS
7-5
AAEDT
AAEDW
AAIAV
AAIKJ
AALRI
AAQFI
AAQQT
AAQXK
AAXUO
AAYOK
ABCQX
ABJNI
ABLJU
ABMAC
ABOCM
ADBBV
ADMUD
ADPAM
AENEX
AEVXI
AFCTW
AFFNX
AFHKK
AFRHN
AFTJW
AGHFR
AGZHU
AHPSJ
AI.
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
ALXNB
AMRAJ
ASPBG
AVWKF
AZFZN
BELOY
BR6
C5W
CAG
COF
CS3
DU5
EBS
EFJIC
EJD
F5P
FD8
FDB
FEDTE
FGOYB
G8K
GBLVA
HVGLF
HZ~
IHE
J1W
J5H
K-O
KOM
L7B
M41
MO0
N4W
N9A
NQ-
O9-
OC.
OHT
ON0
P2P
PC.
QTD
R2-
RIG
ROL
RPZ
SEL
SES
SJN
SSZ
TWZ
UDS
UGJ
UV1
VH1
WH7
X7M
XH2
Y6R
YQJ
Z5R
ZA5
ZGI
ZXP
AAQOH
AFJKZ
NPM
AAYXX
ABDPE
ACRPL
ADNMO
CITATION
7X8
ID FETCH-LOGICAL-c474t-740cf2c7fb2d14b94f6e86781b73e9a32f6371eedb2ab803044e5556bed205633
ISSN 0016-5085
IngestDate Wed Dec 04 10:41:25 EST 2024
Fri Dec 06 01:19:24 EST 2024
Wed Oct 16 00:38:45 EDT 2024
Fri Feb 23 02:37:51 EST 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c474t-740cf2c7fb2d14b94f6e86781b73e9a32f6371eedb2ab803044e5556bed205633
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://doi.org/10.1053/j.gastro.2020.05.046
PMID 32439497
PQID 2406303813
PQPubID 23479
PageCount 6
ParticipantIDs proquest_miscellaneous_2406303813
crossref_primary_10_1053_j_gastro_2020_05_046
pubmed_primary_32439497
elsevier_sciencedirect_doi_10_1053_j_gastro_2020_05_046
PublicationCentury 2000
PublicationDate July 2023
2023-Jul
2023-07-00
20230701
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: July 2023
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Gastroenterology (New York, N.Y. 1943)
PublicationTitleAlternate Gastroenterology
PublicationYear 2023
Publisher Elsevier Inc
Publisher_xml – name: Elsevier Inc
References Harrison, Wai-Sun Wong, Okanoue (bib2) 2020; 73
Wang, Li, Pickholz (bib16) 2023; 15
Harrison, Goodman, Jabbar (bib3) 2020; 72
Loomba, Mohseni, Lucas (bib38) 2021; 161
Bosch, Thabut, Bendtsen (bib15) 2004; 127
Maeda, Kawada, Seki (bib9) 2003; 278
Thomas, Burns, Audette (bib13) 2016
bib29
Younossi, Ratziu, Loomba (bib50) 2019; 394
Traber, Chou, Zomer (bib12) 2013; 8
Liu, Zhang, Graham (bib46) 2020; 73
Chalasani, Abdelmalek, Garcia-Tsao (bib6) 2020; 158
Luukkonen, Qadri, Ahlholm (bib48) 2022; 76
Rosshart, Herz, Vassallo (bib52) 2019; 365
Villanueva, Albillos, Genesca (bib17) 2016; 63
Majdi, Aoudjehane, Ratziu (bib56) 2020; 72
Butscheid, Hauptvogel, Fritz (bib8) 2007; 60
Marra, Tacke (bib58) 2014; 147
Harrison, Rossi, Paredes (bib22) 2020; 71
Kleiner, Brunt, Wilson (bib26) 2019; 2
Rosshart, Vassallo, Angeletti (bib51) 2017; 171
Ratziu, de Guevara, Safadi (bib37) 2021; 27
D'Ambrosio, Aghemo, Rumi (bib20) 2012; 56
Nachit, Kwanten, Thissen (bib40) 2021; 75
Yuan, Chen, Cui (bib43) 2019; 30
Henderson, Sethi (bib7) 2009; 230
Nascimbeni, Lebray, Fedchuck (bib23) 2015; 13
Henao-Mejia, Elinav, Jin (bib53) 2012; 482
Meijnikman, Davids, Herrema (bib44) 2022; 28
Garcia-Tsao, Fuchs, Shiffman (bib55) 2019; 69
Iacobini, Menini, Ricci (bib11) 2011; 54
Anania, Dimick-Santos, Mehta (bib33) 2021; 73
Friedman, Ratziu, Harrison (bib59) 2018; 67
Harrison, Abdelmalek, Caldwell (bib1) 2018; 155
Francque, Bedossa, Ratziu (bib30) 2021; 385
Gautheron, Gores, Rodrigues (bib57) 2020; l73
Marcellin, Gane, Buti (bib21) 2013; 381
Davison, Harrison, Cotter (bib27) 2020; 73
Verbeke, Mannaerts, Schierwagen (bib49) 2016; 6
Ratziu, Charlotte, Heurtier (bib34) 2005; 128
Cusi, Orsak, Bril (bib31) 2016; 165
Bajaj, Ng, Schnabl (bib41) 2022; 76
Sellke, Bayarri, Berger (bib24) 2001; 55
Feldstein, Canbay, Angulo (bib54) 2003; 125
Henderson, Mackinnon, Farnworth (bib10) 2006; 103
Garcia-Tsao, Friedman, Iredale (bib18) 2010; 51
Harrison, Ratziu, Dufour (bib4) 2020; 72
Schwabl, Hambruch, Seeland (bib19) 2017; 66
Calle, Amin, Carvajal-Gonzalez (bib36) 2021; 27
Staufer, Huber-Schonauer, Strebinger (bib42) 2022; 77
Bosch, Thabut, Albillos (bib14) 2008; 47
Kleiner, Brunt, Van Natta (bib25) 2005; 41
Mellinger, Winder, Fernandez (bib45) 2021; 73
Loomba, Kayali, Noureddin (bib35) 2018; 155
Sanyal, Chalasani, Kowdley (bib32) 2010; 362
Harrison, Alkhouri, Davison (bib5) 2020; 72
Lambert, Ramos-Roman, Browning (bib39) 2014; 146
Brunt, Clouston, Goodman (bib28) 2022; 76
Speliotes, George (bib47) 2022; 76
Verbeke (10.1053/j.gastro.2020.05.046_bib49) 2016; 6
Feldstein (10.1053/j.gastro.2020.05.046_bib54) 2003; 125
Younossi (10.1053/j.gastro.2020.05.046_bib50) 2019; 394
Harrison (10.1053/j.gastro.2020.05.046_bib22) 2020; 71
Calle (10.1053/j.gastro.2020.05.046_bib36) 2021; 27
Harrison (10.1053/j.gastro.2020.05.046_bib4) 2020; 72
Cusi (10.1053/j.gastro.2020.05.046_bib31) 2016; 165
Meijnikman (10.1053/j.gastro.2020.05.046_bib44) 2022; 28
Henao-Mejia (10.1053/j.gastro.2020.05.046_bib53) 2012; 482
Thomas (10.1053/j.gastro.2020.05.046_bib13) 2016
Kleiner (10.1053/j.gastro.2020.05.046_bib26) 2019; 2
Bosch (10.1053/j.gastro.2020.05.046_bib15) 2004; 127
Iacobini (10.1053/j.gastro.2020.05.046_bib11) 2011; 54
Majdi (10.1053/j.gastro.2020.05.046_bib56) 2020; 72
Lambert (10.1053/j.gastro.2020.05.046_bib39) 2014; 146
Friedman (10.1053/j.gastro.2020.05.046_bib59) 2018; 67
Yuan (10.1053/j.gastro.2020.05.046_bib43) 2019; 30
Butscheid (10.1053/j.gastro.2020.05.046_bib8) 2007; 60
Henderson (10.1053/j.gastro.2020.05.046_bib10) 2006; 103
Loomba (10.1053/j.gastro.2020.05.046_bib35) 2018; 155
Francque (10.1053/j.gastro.2020.05.046_bib30) 2021; 385
Harrison (10.1053/j.gastro.2020.05.046_bib3) 2020; 72
Henderson (10.1053/j.gastro.2020.05.046_bib7) 2009; 230
Garcia-Tsao (10.1053/j.gastro.2020.05.046_bib55) 2019; 69
Marcellin (10.1053/j.gastro.2020.05.046_bib21) 2013; 381
Bosch (10.1053/j.gastro.2020.05.046_bib14) 2008; 47
Garcia-Tsao (10.1053/j.gastro.2020.05.046_bib18) 2010; 51
Mellinger (10.1053/j.gastro.2020.05.046_bib45) 2021; 73
Harrison (10.1053/j.gastro.2020.05.046_bib2) 2020; 73
Nascimbeni (10.1053/j.gastro.2020.05.046_bib23) 2015; 13
Kleiner (10.1053/j.gastro.2020.05.046_bib25) 2005; 41
Davison (10.1053/j.gastro.2020.05.046_bib27) 2020; 73
Bajaj (10.1053/j.gastro.2020.05.046_bib41) 2022; 76
Speliotes (10.1053/j.gastro.2020.05.046_bib47) 2022; 76
Rosshart (10.1053/j.gastro.2020.05.046_bib52) 2019; 365
Anania (10.1053/j.gastro.2020.05.046_bib33) 2021; 73
Staufer (10.1053/j.gastro.2020.05.046_bib42) 2022; 77
Maeda (10.1053/j.gastro.2020.05.046_bib9) 2003; 278
Sellke (10.1053/j.gastro.2020.05.046_bib24) 2001; 55
Harrison (10.1053/j.gastro.2020.05.046_bib5) 2020; 72
Sanyal (10.1053/j.gastro.2020.05.046_bib32) 2010; 362
Villanueva (10.1053/j.gastro.2020.05.046_bib17) 2016; 63
Wang (10.1053/j.gastro.2020.05.046_bib16) 2023; 15
D'Ambrosio (10.1053/j.gastro.2020.05.046_bib20) 2012; 56
Harrison (10.1053/j.gastro.2020.05.046_bib1) 2018; 155
Ratziu (10.1053/j.gastro.2020.05.046_bib34) 2005; 128
Gautheron (10.1053/j.gastro.2020.05.046_bib57) 2020; l73
Ratziu (10.1053/j.gastro.2020.05.046_bib37) 2021; 27
Schwabl (10.1053/j.gastro.2020.05.046_bib19) 2017; 66
Traber (10.1053/j.gastro.2020.05.046_bib12) 2013; 8
Brunt (10.1053/j.gastro.2020.05.046_bib28) 2022; 76
Rosshart (10.1053/j.gastro.2020.05.046_bib51) 2017; 171
Chalasani (10.1053/j.gastro.2020.05.046_bib6) 2020; 158
Nachit (10.1053/j.gastro.2020.05.046_bib40) 2021; 75
Luukkonen (10.1053/j.gastro.2020.05.046_bib48) 2022; 76
Marra (10.1053/j.gastro.2020.05.046_bib58) 2014; 147
Loomba (10.1053/j.gastro.2020.05.046_bib38) 2021; 161
Liu (10.1053/j.gastro.2020.05.046_bib46) 2020; 73
References_xml – volume: 230
  start-page: 160
  year: 2009
  end-page: 171
  ident: bib7
  article-title: The regulation of inflammation by galectin-3
  publication-title: Immunol Rev
  contributor:
    fullname: Sethi
– ident: bib29
  article-title: 89bio Press Releases. 89bio’s Phase 2b ENLIVEN trial of pegozafermin in nonalcoholic steatohepatitis (NASH) achieved high statistical significance on both primary histology endpoints with weekly (QW) and every-two-week (Q2W) dosing at 24 weeks
– volume: 385
  start-page: 1547
  year: 2021
  end-page: 1558
  ident: bib30
  article-title: A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
  publication-title: N Engl J Med
  contributor:
    fullname: Ratziu
– volume: 54
  start-page: 975
  year: 2011
  end-page: 983
  ident: bib11
  article-title: Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver
  publication-title: J Hepatol
  contributor:
    fullname: Ricci
– volume: 15
  year: 2023
  ident: bib16
  article-title: An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis
  publication-title: Sci Transl Med
  contributor:
    fullname: Pickholz
– volume: 73
  start-page: 263
  year: 2020
  end-page: 276
  ident: bib46
  article-title: Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
  publication-title: J Hepatol
  contributor:
    fullname: Graham
– volume: 147
  start-page: 577
  year: 2014
  end-page: 594.e1
  ident: bib58
  article-title: Roles for chemokines in liver disease
  publication-title: Gastroenterology
  contributor:
    fullname: Tacke
– volume: 278
  start-page: 18938
  year: 2003
  end-page: 18944
  ident: bib9
  article-title: Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways
  publication-title: J Biol Chem
  contributor:
    fullname: Seki
– volume: l73
  start-page: 394
  year: 2020
  end-page: 408
  ident: bib57
  article-title: Lytic cell death in metabolic liver disease
  publication-title: J Hepatol
  contributor:
    fullname: Rodrigues
– volume: 72
  start-page: 613
  year: 2020
  end-page: 626
  ident: bib5
  article-title: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study
  publication-title: J Hepatol
  contributor:
    fullname: Davison
– volume: 27
  start-page: 1825
  year: 2021
  end-page: 1835
  ident: bib37
  article-title: Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
  publication-title: Nat Med
  contributor:
    fullname: Safadi
– volume: 73
  start-page: 1322
  year: 2020
  end-page: 1332
  ident: bib27
  article-title: Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
  publication-title: J Hepatol
  contributor:
    fullname: Cotter
– volume: 75
  start-page: 292
  year: 2021
  end-page: 301
  ident: bib40
  article-title: Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity
  publication-title: J Hepatol
  contributor:
    fullname: Thissen
– volume: 60
  start-page: 415
  year: 2007
  end-page: 418
  ident: bib8
  article-title: Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease
  publication-title: J Clin Pathol
  contributor:
    fullname: Fritz
– volume: 73
  start-page: 2023
  year: 2021
  end-page: 2027
  ident: bib33
  article-title: Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration
  publication-title: Hepatology
  contributor:
    fullname: Mehta
– volume: 76
  start-page: 526
  year: 2022
  end-page: 535
  ident: bib48
  article-title: Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
  publication-title: J Hepatol
  contributor:
    fullname: Ahlholm
– volume: 381
  start-page: 468
  year: 2013
  end-page: 475
  ident: bib21
  article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
  publication-title: Lancet
  contributor:
    fullname: Buti
– volume: 69
  start-page: 717
  year: 2019
  end-page: 728
  ident: bib55
  article-title: Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
  publication-title: Hepatology
  contributor:
    fullname: Shiffman
– volume: 6
  year: 2016
  ident: bib49
  article-title: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
  publication-title: Sci Rep
  contributor:
    fullname: Schierwagen
– volume: 72
  start-page: 627
  year: 2020
  end-page: 635
  ident: bib56
  article-title: Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
  publication-title: J Hepatol
  contributor:
    fullname: Ratziu
– volume: 73
  start-page: 26
  year: 2020
  end-page: 39
  ident: bib2
  article-title: Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Ph III STELLAR trials
  publication-title: J Hepatol
  contributor:
    fullname: Okanoue
– volume: 51
  start-page: 1445
  year: 2010
  end-page: 1449
  ident: bib18
  article-title: Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis
  publication-title: Hepatology
  contributor:
    fullname: Iredale
– volume: 73
  start-page: 1207
  year: 2021
  end-page: 1212
  ident: bib45
  article-title: Measuring the alcohol in alcohol-associated liver disease: choices and challenges for clinical research
  publication-title: Hepatology
  contributor:
    fullname: Fernandez
– volume: 127
  start-page: 1123
  year: 2004
  end-page: 1130
  ident: bib15
  article-title: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial
  publication-title: Gastroenterology
  contributor:
    fullname: Bendtsen
– volume: 158
  start-page: 1334
  year: 2020
  end-page: 1345.e5
  ident: bib6
  article-title: Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension
  publication-title: Gastroenterology
  contributor:
    fullname: Garcia-Tsao
– volume: 146
  start-page: 726
  year: 2014
  end-page: 735
  ident: bib39
  article-title: Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  contributor:
    fullname: Browning
– volume: 47
  start-page: 1604
  year: 2008
  end-page: 1614
  ident: bib14
  article-title: Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial
  publication-title: Hepatology
  contributor:
    fullname: Albillos
– volume: 8
  year: 2013
  ident: bib12
  article-title: Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease
  publication-title: PLoS One
  contributor:
    fullname: Zomer
– volume: 362
  start-page: 1675
  year: 2010
  end-page: 1685
  ident: bib32
  article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
  publication-title: N Engl J Med
  contributor:
    fullname: Kowdley
– volume: 63
  start-page: 197
  year: 2016
  end-page: 206
  ident: bib17
  article-title: Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension
  publication-title: Hepatology
  contributor:
    fullname: Genesca
– volume: 76
  start-page: 1030
  year: 2022
  end-page: 1041
  ident: bib28
  article-title: Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD
  publication-title: J Hepatol
  contributor:
    fullname: Goodman
– volume: 71
  start-page: 1198
  year: 2020
  end-page: 1212
  ident: bib22
  article-title: NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis
  publication-title: Hepatology
  contributor:
    fullname: Paredes
– volume: 55
  start-page: 62
  year: 2001
  end-page: 71
  ident: bib24
  article-title: Calibration of ρ values for testing precise null hypotheses
  publication-title: Am Stat
  contributor:
    fullname: Berger
– volume: 2
  year: 2019
  ident: bib26
  article-title: Association of histologic disease activity with progression of nonalcoholic fatty liver disease
  publication-title: JAMA Netw Open
  contributor:
    fullname: Wilson
– volume: 27
  start-page: 1836
  year: 2021
  end-page: 1848
  ident: bib36
  article-title: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
  publication-title: Nat Med
  contributor:
    fullname: Carvajal-Gonzalez
– volume: 161
  start-page: 1475
  year: 2021
  end-page: 1486
  ident: bib38
  article-title: TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial
  publication-title: Gastroenterology
  contributor:
    fullname: Lucas
– volume: 56
  start-page: 532
  year: 2012
  end-page: 543
  ident: bib20
  article-title: A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
  publication-title: Hepatology
  contributor:
    fullname: Rumi
– volume: 76
  start-page: 498
  year: 2022
  end-page: 500
  ident: bib47
  article-title: Metabolic and genetic contributions to NAFLD: really distinct and homogeneous?
  publication-title: J Hepatol
  contributor:
    fullname: George
– volume: 77
  start-page: 918
  year: 2022
  end-page: 930
  ident: bib42
  article-title: Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease
  publication-title: J Hepatol
  contributor:
    fullname: Strebinger
– volume: 41
  start-page: 1313
  year: 2005
  end-page: 1321
  ident: bib25
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  contributor:
    fullname: Van Natta
– volume: 72
  start-page: 816
  year: 2020
  end-page: 827
  ident: bib3
  article-title: A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
  publication-title: J Hepatol
  contributor:
    fullname: Jabbar
– volume: 76
  start-page: 1379
  year: 2022
  end-page: 1391
  ident: bib41
  article-title: Promises of microbiome-based therapies
  publication-title: J Hepatol
  contributor:
    fullname: Schnabl
– volume: 103
  start-page: 5060
  year: 2006
  end-page: 5065
  ident: bib10
  article-title: Galectin-3 regulates myofibroblast activation and hepatic fibrosis
  publication-title: Proc Natl Acad Sci U S A
  contributor:
    fullname: Farnworth
– volume: 67
  start-page: 1754
  year: 2018
  end-page: 1767
  ident: bib59
  article-title: A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
  publication-title: Hepatology
  contributor:
    fullname: Harrison
– volume: 125
  start-page: 437
  year: 2003
  end-page: 443
  ident: bib54
  article-title: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  contributor:
    fullname: Angulo
– volume: 72
  start-page: LP23
  year: 2020
  ident: bib4
  article-title: The dual PPARα/δ agonist elafibranor did not achieve resolution of NASH without worsening of fibrosis in adult patients with non-alcoholic steatohepatitis and significant fibrosis
  publication-title: Hepatology
  contributor:
    fullname: Dufour
– volume: 171
  start-page: 1015
  year: 2017
  end-page: 1028.e13
  ident: bib51
  article-title: Wild mouse gut microbiota promotes host fitness and improves disease resistance
  publication-title: Cell
  contributor:
    fullname: Angeletti
– volume: 30
  start-page: 1172
  year: 2019
  ident: bib43
  article-title: Fatty liver disease caused by high-alcohol-producing
  publication-title: Cell Metab
  contributor:
    fullname: Cui
– volume: 28
  start-page: 2100
  year: 2022
  end-page: 2106
  ident: bib44
  article-title: Microbiome-derived ethanol in nonalcoholic fatty liver disease
  publication-title: Nat Med
  contributor:
    fullname: Herrema
– volume: 165
  start-page: 305
  year: 2016
  end-page: 315
  ident: bib31
  article-title: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial
  publication-title: Ann Intern Med
  contributor:
    fullname: Bril
– volume: 128
  start-page: 1898
  year: 2005
  end-page: 1906
  ident: bib34
  article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  contributor:
    fullname: Heurtier
– year: 2016
  ident: bib13
  article-title: Clinical Development Success Rates 2006-2015
  contributor:
    fullname: Audette
– volume: 155
  start-page: 1140
  year: 2018
  end-page: 1153
  ident: bib1
  article-title: Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  contributor:
    fullname: Caldwell
– volume: 13
  start-page: 763
  year: 2015
  end-page: 771
  ident: bib23
  article-title: Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases
  publication-title: Clin Gastroenterol Hepatol
  contributor:
    fullname: Fedchuck
– volume: 155
  start-page: 1463
  year: 2018
  end-page: 1473.e6
  ident: bib35
  article-title: GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  contributor:
    fullname: Noureddin
– volume: 365
  year: 2019
  ident: bib52
  article-title: Laboratory mice born to wild mice have natural microbiota and model human immune responses
  publication-title: Science
  contributor:
    fullname: Vassallo
– volume: 66
  start-page: 724
  year: 2017
  end-page: 733
  ident: bib19
  article-title: The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
  publication-title: J Hepatol
  contributor:
    fullname: Seeland
– volume: 482
  start-page: 179
  year: 2012
  end-page: 185
  ident: bib53
  article-title: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
  publication-title: Nature
  contributor:
    fullname: Jin
– volume: 394
  start-page: 2184
  year: 2019
  end-page: 2196
  ident: bib50
  article-title: Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
  publication-title: Lancet
  contributor:
    fullname: Loomba
– volume: 6
  year: 2016
  ident: 10.1053/j.gastro.2020.05.046_bib49
  article-title: FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
  publication-title: Sci Rep
  doi: 10.1038/srep33453
  contributor:
    fullname: Verbeke
– volume: 15
  year: 2023
  ident: 10.1053/j.gastro.2020.05.046_bib16
  article-title: An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.add3949
  contributor:
    fullname: Wang
– volume: 30
  start-page: 1172
  year: 2019
  ident: 10.1053/j.gastro.2020.05.046_bib43
  article-title: Fatty liver disease caused by high-alcohol-producing Klebsiella pneumoniae
  publication-title: Cell Metab
  doi: 10.1016/j.cmet.2019.11.006
  contributor:
    fullname: Yuan
– volume: 158
  start-page: 1334
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib6
  article-title: Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2019.11.296
  contributor:
    fullname: Chalasani
– volume: 55
  start-page: 62
  year: 2001
  ident: 10.1053/j.gastro.2020.05.046_bib24
  article-title: Calibration of ρ values for testing precise null hypotheses
  publication-title: Am Stat
  doi: 10.1198/000313001300339950
  contributor:
    fullname: Sellke
– year: 2016
  ident: 10.1053/j.gastro.2020.05.046_bib13
  contributor:
    fullname: Thomas
– volume: 385
  start-page: 1547
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib30
  article-title: A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2036205
  contributor:
    fullname: Francque
– volume: 76
  start-page: 1030
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib28
  article-title: Complexity of ballooned hepatocyte feature recognition: defining a training atlas for artificial intelligence-based imaging in NAFLD
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2022.01.011
  contributor:
    fullname: Brunt
– volume: 161
  start-page: 1475
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib38
  article-title: TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2021.07.025
  contributor:
    fullname: Loomba
– volume: 76
  start-page: 498
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib47
  article-title: Metabolic and genetic contributions to NAFLD: really distinct and homogeneous?
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.12.024
  contributor:
    fullname: Speliotes
– volume: 60
  start-page: 415
  year: 2007
  ident: 10.1053/j.gastro.2020.05.046_bib8
  article-title: Hepatic expression of galectin-3 and receptor for advanced glycation end products in patients with liver disease
  publication-title: J Clin Pathol
  doi: 10.1136/jcp.2005.032391
  contributor:
    fullname: Butscheid
– volume: 72
  start-page: 627
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib56
  article-title: Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.11.008
  contributor:
    fullname: Majdi
– volume: 69
  start-page: 717
  year: 2019
  ident: 10.1053/j.gastro.2020.05.046_bib55
  article-title: Emricasan (IDN-6556) lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension
  publication-title: Hepatology
  doi: 10.1002/hep.30199
  contributor:
    fullname: Garcia-Tsao
– volume: 72
  start-page: 613
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib5
  article-title: Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase IIb study
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.10.023
  contributor:
    fullname: Harrison
– volume: 146
  start-page: 726
  year: 2014
  ident: 10.1053/j.gastro.2020.05.046_bib39
  article-title: Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2013.11.049
  contributor:
    fullname: Lambert
– volume: 8
  year: 2013
  ident: 10.1053/j.gastro.2020.05.046_bib12
  article-title: Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0075361
  contributor:
    fullname: Traber
– volume: 155
  start-page: 1463
  year: 2018
  ident: 10.1053/j.gastro.2020.05.046_bib35
  article-title: GS-0976 reduces hepatic steatosis and fibrosis markers in patients with nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.07.027
  contributor:
    fullname: Loomba
– volume: 75
  start-page: 292
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib40
  article-title: Muscle fat content is strongly associated with NASH: a longitudinal study in patients with morbid obesity
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.02.037
  contributor:
    fullname: Nachit
– volume: 278
  start-page: 18938
  year: 2003
  ident: 10.1053/j.gastro.2020.05.046_bib9
  article-title: Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M209673200
  contributor:
    fullname: Maeda
– volume: 56
  start-page: 532
  year: 2012
  ident: 10.1053/j.gastro.2020.05.046_bib20
  article-title: A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
  publication-title: Hepatology
  doi: 10.1002/hep.25606
  contributor:
    fullname: D'Ambrosio
– volume: 28
  start-page: 2100
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib44
  article-title: Microbiome-derived ethanol in nonalcoholic fatty liver disease
  publication-title: Nat Med
  doi: 10.1038/s41591-022-02016-6
  contributor:
    fullname: Meijnikman
– volume: 103
  start-page: 5060
  year: 2006
  ident: 10.1053/j.gastro.2020.05.046_bib10
  article-title: Galectin-3 regulates myofibroblast activation and hepatic fibrosis
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0511167103
  contributor:
    fullname: Henderson
– volume: 71
  start-page: 1198
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib22
  article-title: NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis
  publication-title: Hepatology
  doi: 10.1002/hep.30590
  contributor:
    fullname: Harrison
– volume: 2
  year: 2019
  ident: 10.1053/j.gastro.2020.05.046_bib26
  article-title: Association of histologic disease activity with progression of nonalcoholic fatty liver disease
  publication-title: JAMA Netw Open
  doi: 10.1001/jamanetworkopen.2019.12565
  contributor:
    fullname: Kleiner
– volume: 63
  start-page: 197
  year: 2016
  ident: 10.1053/j.gastro.2020.05.046_bib17
  article-title: Development of hyperdynamic circulation and response to beta-blockers in compensated cirrhosis with portal hypertension
  publication-title: Hepatology
  doi: 10.1002/hep.28264
  contributor:
    fullname: Villanueva
– volume: 165
  start-page: 305
  year: 2016
  ident: 10.1053/j.gastro.2020.05.046_bib31
  article-title: Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial
  publication-title: Ann Intern Med
  doi: 10.7326/M15-1774
  contributor:
    fullname: Cusi
– volume: 381
  start-page: 468
  year: 2013
  ident: 10.1053/j.gastro.2020.05.046_bib21
  article-title: Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(12)61425-1
  contributor:
    fullname: Marcellin
– volume: 128
  start-page: 1898
  year: 2005
  ident: 10.1053/j.gastro.2020.05.046_bib34
  article-title: Sampling variability of liver biopsy in nonalcoholic fatty liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2005.03.084
  contributor:
    fullname: Ratziu
– volume: 482
  start-page: 179
  year: 2012
  ident: 10.1053/j.gastro.2020.05.046_bib53
  article-title: Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
  publication-title: Nature
  doi: 10.1038/nature10809
  contributor:
    fullname: Henao-Mejia
– volume: 76
  start-page: 1379
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib41
  article-title: Promises of microbiome-based therapies
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.12.003
  contributor:
    fullname: Bajaj
– volume: 171
  start-page: 1015
  year: 2017
  ident: 10.1053/j.gastro.2020.05.046_bib51
  article-title: Wild mouse gut microbiota promotes host fitness and improves disease resistance
  publication-title: Cell
  doi: 10.1016/j.cell.2017.09.016
  contributor:
    fullname: Rosshart
– volume: 73
  start-page: 26
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib2
  article-title: Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Ph III STELLAR trials
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.02.027
  contributor:
    fullname: Harrison
– volume: 73
  start-page: 1207
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib45
  article-title: Measuring the alcohol in alcohol-associated liver disease: choices and challenges for clinical research
  publication-title: Hepatology
  doi: 10.1002/hep.31539
  contributor:
    fullname: Mellinger
– volume: 155
  start-page: 1140
  year: 2018
  ident: 10.1053/j.gastro.2020.05.046_bib1
  article-title: Simtuzumab is ineffective for patients with bridging fibrosis or compensated cirrhosis caused by nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2018.07.006
  contributor:
    fullname: Harrison
– volume: 72
  start-page: 816
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib3
  article-title: A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2019.11.024
  contributor:
    fullname: Harrison
– volume: 125
  start-page: 437
  year: 2003
  ident: 10.1053/j.gastro.2020.05.046_bib54
  article-title: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
  publication-title: Gastroenterology
  doi: 10.1016/S0016-5085(03)00907-7
  contributor:
    fullname: Feldstein
– volume: 72
  start-page: LP23
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib4
  article-title: The dual PPARα/δ agonist elafibranor did not achieve resolution of NASH without worsening of fibrosis in adult patients with non-alcoholic steatohepatitis and significant fibrosis
  publication-title: Hepatology
  contributor:
    fullname: Harrison
– volume: 73
  start-page: 1322
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib27
  article-title: Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.06.025
  contributor:
    fullname: Davison
– volume: 67
  start-page: 1754
  year: 2018
  ident: 10.1053/j.gastro.2020.05.046_bib59
  article-title: A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
  publication-title: Hepatology
  doi: 10.1002/hep.29477
  contributor:
    fullname: Friedman
– volume: 51
  start-page: 1445
  year: 2010
  ident: 10.1053/j.gastro.2020.05.046_bib18
  article-title: Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis
  publication-title: Hepatology
  doi: 10.1002/hep.23478
  contributor:
    fullname: Garcia-Tsao
– volume: 362
  start-page: 1675
  year: 2010
  ident: 10.1053/j.gastro.2020.05.046_bib32
  article-title: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa0907929
  contributor:
    fullname: Sanyal
– volume: 27
  start-page: 1836
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib36
  article-title: ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01489-1
  contributor:
    fullname: Calle
– volume: 77
  start-page: 918
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib42
  article-title: Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2022.04.040
  contributor:
    fullname: Staufer
– volume: 230
  start-page: 160
  year: 2009
  ident: 10.1053/j.gastro.2020.05.046_bib7
  article-title: The regulation of inflammation by galectin-3
  publication-title: Immunol Rev
  doi: 10.1111/j.1600-065X.2009.00794.x
  contributor:
    fullname: Henderson
– volume: 147
  start-page: 577
  year: 2014
  ident: 10.1053/j.gastro.2020.05.046_bib58
  article-title: Roles for chemokines in liver disease
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2014.06.043
  contributor:
    fullname: Marra
– volume: 54
  start-page: 975
  year: 2011
  ident: 10.1053/j.gastro.2020.05.046_bib11
  article-title: Galectin-3 ablation protects mice from diet-induced NASH: a major scavenging role for galectin-3 in liver
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2010.09.020
  contributor:
    fullname: Iacobini
– volume: 41
  start-page: 1313
  year: 2005
  ident: 10.1053/j.gastro.2020.05.046_bib25
  article-title: Design and validation of a histological scoring system for nonalcoholic fatty liver disease
  publication-title: Hepatology
  doi: 10.1002/hep.20701
  contributor:
    fullname: Kleiner
– volume: 365
  issue: 6452
  year: 2019
  ident: 10.1053/j.gastro.2020.05.046_bib52
  article-title: Laboratory mice born to wild mice have natural microbiota and model human immune responses
  publication-title: Science
  doi: 10.1126/science.aaw4361
  contributor:
    fullname: Rosshart
– volume: 13
  start-page: 763
  year: 2015
  ident: 10.1053/j.gastro.2020.05.046_bib23
  article-title: Significant variations in elastometry measurements made within short-term in patients with chronic liver diseases
  publication-title: Clin Gastroenterol Hepatol
  doi: 10.1016/j.cgh.2014.07.037
  contributor:
    fullname: Nascimbeni
– volume: 76
  start-page: 526
  year: 2022
  ident: 10.1053/j.gastro.2020.05.046_bib48
  article-title: Distinct contributions of metabolic dysfunction and genetic risk factors in the pathogenesis of non-alcoholic fatty liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2021.10.013
  contributor:
    fullname: Luukkonen
– volume: 127
  start-page: 1123
  year: 2004
  ident: 10.1053/j.gastro.2020.05.046_bib15
  article-title: Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2004.07.015
  contributor:
    fullname: Bosch
– volume: 47
  start-page: 1604
  year: 2008
  ident: 10.1053/j.gastro.2020.05.046_bib14
  article-title: Recombinant factor VIIa for variceal bleeding in patients with advanced cirrhosis: a randomized, controlled trial
  publication-title: Hepatology
  doi: 10.1002/hep.22216
  contributor:
    fullname: Bosch
– volume: l73
  start-page: 394
  issue: 2
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib57
  article-title: Lytic cell death in metabolic liver disease
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.04.001
  contributor:
    fullname: Gautheron
– volume: 73
  start-page: 263
  year: 2020
  ident: 10.1053/j.gastro.2020.05.046_bib46
  article-title: Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2020.03.006
  contributor:
    fullname: Liu
– volume: 27
  start-page: 1825
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib37
  article-title: Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial
  publication-title: Nat Med
  doi: 10.1038/s41591-021-01495-3
  contributor:
    fullname: Ratziu
– volume: 66
  start-page: 724
  year: 2017
  ident: 10.1053/j.gastro.2020.05.046_bib19
  article-title: The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction
  publication-title: J Hepatol
  doi: 10.1016/j.jhep.2016.12.005
  contributor:
    fullname: Schwabl
– volume: 73
  start-page: 2023
  year: 2021
  ident: 10.1053/j.gastro.2020.05.046_bib33
  article-title: Nonalcoholic steatohepatitis: current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration
  publication-title: Hepatology
  doi: 10.1002/hep.31687
  contributor:
    fullname: Anania
– volume: 394
  start-page: 2184
  year: 2019
  ident: 10.1053/j.gastro.2020.05.046_bib50
  article-title: Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
  publication-title: Lancet
  doi: 10.1016/S0140-6736(19)33041-7
  contributor:
    fullname: Younossi
SSID ssj0009381
Score 2.663687
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 5
Title Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?
URI https://dx.doi.org/10.1053/j.gastro.2020.05.046
https://www.ncbi.nlm.nih.gov/pubmed/32439497
https://search.proquest.com/docview/2406303813
Volume 165
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9wwELbaRUJcUN9dWipX6i0KTfzI41RRWkAVcChLy82yHacsgg3azR7g13dsx8uy2lUflyhKFCeZbzL5ZjyeQegDq7PMhtdiQjSLGUnquDQFjytGGS9SySppA_rHJ9nhGft2zs9DW_ZudUmrdvTd0nUl_4MqHANc7SrZf0B2NigcgH3AF7aAMGz_CuOfF7fAgKPTxmax3EYnllW7jrdDbdO3wJ--MDZjuh1OooF7nmhfDq8WkvkO5KQdN7Y259gXZFrSoCdKSzYfk_0u27vh1CXJXslqpgTgd1chpOqKPhzNRxUInWWgwk-hs4S2dHWSPjSVvq_DA53who8vNceJ66lxufPLvQh44yRxdVJ91HEOoZtrBxGwO1oyn7C7UAY7nHqM1mzNQ9ZDawefj37s3ldYBu4R1kZy-nHZTTfQehhmFQ1Z5WY4ujF4gjY7PwHvetCfokdm9AytH3eZEM9RAdjjLw0-bbDFHs9jjxewxx57bLH_9AKd7X8d7B3GXReMWLOctXHOEl0TndeKVClTJXxdpgCKkaqcmlJSUmc0T4HqKCJVYWe6meGcZ8pUBNgtpS9Rb9SMzGuEdaXqXCqQhC6ZYmlhEioLDVZdptZ891EchCJufLET4ZIUOAUn0ctTWHmKhAsYpY_yIDnRETZPxAQowB-ufB8ELcCe2UkqOTLNdCIsw6R2-pr20SuPwOxZAnhbK8-8QRv32vwW9drx1GwDa2zVu05ffgPUo2cw
link.rule.ids 314,780,784,27924,27925
linkProvider Elsevier
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Why+Do+So+Many+Nonalcoholic+Steatohepatitis+Trials+Fail%3F&rft.jtitle=Gastroenterology+%28New+York%2C+N.Y.+1943%29&rft.au=Ratziu%2C+Vlad&rft.au=Friedman%2C+Scott+L&rft.date=2023-07-01&rft.eissn=1528-0012&rft.volume=165&rft.issue=1&rft.spage=5&rft_id=info:doi/10.1053%2Fj.gastro.2020.05.046&rft_id=info%3Apmid%2F32439497&rft.externalDocID=32439497
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0016-5085&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0016-5085&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0016-5085&client=summon